SCF AEIC API DISCOVERY MAP

HIV/AIDS-Equivalent Immune Collapse (AEIC)

Document Code: SCF-AEIC-ADM-0001

Framework Integration:

SCF Gene-Class Atlas (AEIC)
SCF AEIC Gene Library
SCF AEIC Target Priority Matrix
SCF Synergistic Compatibility Framework (SCF)
SCF API Discovery Profile Generator
FDA Translational Drug Development Pathway

Purpose:

Translate Tier-1 and Tier-2 AEIC targets into candidate therapeutic APIs, synergistic stacks, and delivery architectures aligned with SCF drug-design principles.

1. Discovery Map Architecture

The SCF AEIC API Discovery Map links five structural layers:

Layer	Function
Gene Targets	Molecular control nodes
Mechanistic Axis	Biological pathway
API Candidates	Synthetic or botanical molecules
SCF Role Assignment	Functional synergy role
Delivery System	Pharmacokinetic optimization

The discovery map is designed to support:

multi-target therapeutic stacks
resistance-prevention architecture
pharmacokinetic optimization
safety harmonization

2. AEIC Therapeutic Axis Framework

AEIC therapeutic reconstruction requires intervention across five SCF restoration domains:

SCF Restoration Axis	Biological Target
Viral Entry Control	CCR5, CXCR4
Immune Circuit Restoration	IL2, IL7, PD-1
Antiviral Restriction Activation	APOBEC3G, IFITM3
Metabolic Recovery	AMPK, mTOR
Xenobiotic Suppression	AhR pathway

These axes represent the minimum therapeutic coverage required for immune restoration.

3. Target-to-API Mapping Matrix

Target	Mechanistic Axis	API Candidates	SCF Role
CCR5	viral entry	maraviroc	target-specific modulator
CXCR4	viral entry	plerixafor	receptor antagonist
PD-1	immune exhaustion	nivolumab	checkpoint inhibitor
CTLA4	immune suppression	ipilimumab	immune activation
IL2	T-cell expansion	aldesleukin	immune restoration
IL7	lymphocyte survival	recombinant IL-7	immune regeneration
MTOR	metabolic regulation	rapamycin analogs	metabolic regulator
AMPK	energy homeostasis	metformin derivatives	metabolic activator
AHR	xenobiotic suppression	AhR antagonists	immune stabilizer
APOBEC3G	antiviral restriction	APOBEC activators	viral replication inhibitor
IFITM3	viral membrane block	IFN-induced pathways	antiviral enhancer
TRIM5	capsid restriction	TRIM5 agonists	viral replication restriction
BST2	viral budding inhibition	tetherin activators	viral release inhibitor

4. Botanical-Derived API Discovery Layer

SCF ethnobioprospecting identifies natural molecules with compatible mechanisms.

Molecule	Source	Target Axis	SCF Role
quercetin	plants (various)	antiviral signaling	metabolic regulator
berberine	Berberis species	AMPK activation	metabolic stabilizer
curcumin	Curcuma longa	NF-κB inhibition	immune modulator
resveratrol	Vitis vinifera	mitochondrial function	metabolic enhancer
epigallocatechin gallate	Camellia sinensis	antiviral restriction	immune regulator
andrographolide	Andrographis paniculata	cytokine modulation	immune stabilizer

These molecules serve as lead scaffolds for semi-synthetic API development.

5. SCF Synthetic API Scaffold Design

API Scaffold Class 1

CCR5-Selective Antagonists

Target function: viral entry inhibition

Example scaffold:

SMILES structure

C1=CC=C(C=C1)N(CC2=NC=NC=N2)C3=CC=CC=C3

Role: receptor binding blockade

API Scaffold Class 2

AMPK Activation Molecules

Target function: immune metabolic restoration

Example scaffold:

CC1=NC=NC2=C1N=CN2C3OC(CO)C(O)C3O

Role: mitochondrial energy stabilization

API Scaffold Class 3

AhR Pathway Antagonists

Target function: xenobiotic immune suppression blockade

Example scaffold:

C1=CC=C2C(=C1)C=CC=C2N3CCN(CC3)C

Role: toxin-induced immune suppression reversal

6. SCF Synergistic Therapeutic Stack

SCF Fibonacci Stack Design

Position	Component	Target
1	CCR5 inhibitor	viral entry
1	antiviral restriction activator	viral replication
2	immune checkpoint modulator	T-cell exhaustion
3	AMPK metabolic activator	immune energy
5	antioxidant / redox stabilizer	oxidative stress

This configuration ensures:

resistance barrier
metabolic stabilization
immune recovery

7. Pharmacokinetic Optimization Layer

Strategy	Function
lipid nanoparticle delivery	immune tissue targeting
lymphatic drug carriers	lymph node concentration
prodrug activation	metabolic efficiency
sustained-release implants	viral suppression continuity

8. Resistance Prevention Architecture

The SCF strategy prevents viral escape through multi-axis blockade:

Escape Mechanism	SCF Countermeasure
receptor mutation	dual CCR5/CXCR4 inhibition
replication mutation	APOBEC activation
immune exhaustion	checkpoint inhibition
metabolic collapse	AMPK activation

9. Translational Blueprint

Preclinical Development

viral replication assays
immune exhaustion profiling
cytokine network analysis
mitochondrial energy testing

Clinical Endpoints

Endpoint	Measurement
immune restoration	CD4 recovery
viral suppression	viral load
metabolic recovery	ATP:cAMP ratio
inflammatory balance	cytokine panel

10. Integration with Project RHENOVA

The AEIC API Discovery Map provides the molecular foundation for RHENOVA programs focused on:

immune system reconstruction
antiviral therapeutic stacks
xenobiotic-viral convergence modeling

11. Strategic Next Research Pathway

Next document in the SCF development chain:

SCF AEIC THERAPEUTIC STACK BLUEPRINT

This document converts the discovery map into:

final drug combinations
dosing architecture
pharmacokinetic modeling
IND-ready preclinical development plan

12. SCF Master Registry Index

SCF-AEIC-ADM-0001

SCF-AEIC-TPM-0001

SCF-AEIC-GL-0001

SCF-GCA-AEIC-0001

SCF-SEF-MD-0001

SCF-API-DP-0001

SCF-PP-UVT-0001

SCF-CRD-WORKFLOW-0001

SCF-VECTIS-409-PIPELINE-0001

SCF AEIC API DISCOVERY MAP

HIV/AIDS-Equivalent Immune Collapse (AEIC)

Document Code: SCF-AEIC-ADM-0001

Framework Integration:

SCF Gene-Class Atlas (AEIC)
SCF AEIC Gene Library
SCF AEIC Target Priority Matrix
SCF Synergistic Compatibility Framework (SCF)
SCF API Discovery Profile Generator
FDA Translational Drug Development Pathway

Purpose:

Translate Tier-1 and Tier-2 AEIC targets into candidate therapeutic APIs, synergistic stacks, and delivery architectures aligned with SCF drug-design principles.

1. Discovery Map Architecture

The SCF AEIC API Discovery Map links five structural layers:

Layer	Function
Gene Targets	Molecular control nodes
Mechanistic Axis	Biological pathway
API Candidates	Synthetic or botanical molecules
SCF Role Assignment	Functional synergy role
Delivery System	Pharmacokinetic optimization

The discovery map is designed to support:

multi-target therapeutic stacks
resistance-prevention architecture
pharmacokinetic optimization
safety harmonization

2. AEIC Therapeutic Axis Framework

AEIC therapeutic reconstruction requires intervention across five SCF restoration domains:

SCF Restoration Axis	Biological Target
Viral Entry Control	CCR5, CXCR4
Immune Circuit Restoration	IL2, IL7, PD-1
Antiviral Restriction Activation	APOBEC3G, IFITM3
Metabolic Recovery	AMPK, mTOR
Xenobiotic Suppression	AhR pathway

These axes represent the minimum therapeutic coverage required for immune restoration.

3. Target-to-API Mapping Matrix

Target	Mechanistic Axis	API Candidates	SCF Role
CCR5	viral entry	maraviroc	target-specific modulator
CXCR4	viral entry	plerixafor	receptor antagonist
PD-1	immune exhaustion	nivolumab	checkpoint inhibitor
CTLA4	immune suppression	ipilimumab	immune activation
IL2	T-cell expansion	aldesleukin	immune restoration
IL7	lymphocyte survival	recombinant IL-7	immune regeneration
MTOR	metabolic regulation	rapamycin analogs	metabolic regulator
AMPK	energy homeostasis	metformin derivatives	metabolic activator
AHR	xenobiotic suppression	AhR antagonists	immune stabilizer
APOBEC3G	antiviral restriction	APOBEC activators	viral replication inhibitor
IFITM3	viral membrane block	IFN-induced pathways	antiviral enhancer
TRIM5	capsid restriction	TRIM5 agonists	viral replication restriction
BST2	viral budding inhibition	tetherin activators	viral release inhibitor

4. Botanical-Derived API Discovery Layer

SCF ethnobioprospecting identifies natural molecules with compatible mechanisms.

Molecule	Source	Target Axis	SCF Role
quercetin	plants (various)	antiviral signaling	metabolic regulator
berberine	Berberis species	AMPK activation	metabolic stabilizer
curcumin	Curcuma longa	NF-κB inhibition	immune modulator
resveratrol	Vitis vinifera	mitochondrial function	metabolic enhancer
epigallocatechin gallate	Camellia sinensis	antiviral restriction	immune regulator
andrographolide	Andrographis paniculata	cytokine modulation	immune stabilizer

These molecules serve as lead scaffolds for semi-synthetic API development.

5. SCF Synthetic API Scaffold Design

API Scaffold Class 1

CCR5-Selective Antagonists

Target function: viral entry inhibition

Example scaffold:

SMILES structure

C1=CC=C(C=C1)N(CC2=NC=NC=N2)C3=CC=CC=C3

Role: receptor binding blockade

API Scaffold Class 2

AMPK Activation Molecules

Target function: immune metabolic restoration

Example scaffold:

CC1=NC=NC2=C1N=CN2C3OC(CO)C(O)C3O

Role: mitochondrial energy stabilization

API Scaffold Class 3

AhR Pathway Antagonists

Target function: xenobiotic immune suppression blockade

Example scaffold:

C1=CC=C2C(=C1)C=CC=C2N3CCN(CC3)C

Role: toxin-induced immune suppression reversal

6. SCF Synergistic Therapeutic Stack

SCF Fibonacci Stack Design

Position	Component	Target
1	CCR5 inhibitor	viral entry
1	antiviral restriction activator	viral replication
2	immune checkpoint modulator	T-cell exhaustion
3	AMPK metabolic activator	immune energy
5	antioxidant / redox stabilizer	oxidative stress

This configuration ensures:

resistance barrier
metabolic stabilization
immune recovery

7. Pharmacokinetic Optimization Layer

Strategy	Function
lipid nanoparticle delivery	immune tissue targeting
lymphatic drug carriers	lymph node concentration
prodrug activation	metabolic efficiency
sustained-release implants	viral suppression continuity

8. Resistance Prevention Architecture

The SCF strategy prevents viral escape through multi-axis blockade:

Escape Mechanism	SCF Countermeasure
receptor mutation	dual CCR5/CXCR4 inhibition
replication mutation	APOBEC activation
immune exhaustion	checkpoint inhibition
metabolic collapse	AMPK activation

9. Translational Blueprint

Preclinical Development

viral replication assays
immune exhaustion profiling
cytokine network analysis
mitochondrial energy testing

Clinical Endpoints

Endpoint	Measurement
immune restoration	CD4 recovery
viral suppression	viral load
metabolic recovery	ATP:cAMP ratio
inflammatory balance	cytokine panel

10. Integration with Project RHENOVA

The AEIC API Discovery Map provides the molecular foundation for RHENOVA programs focused on:

immune system reconstruction
antiviral therapeutic stacks
xenobiotic-viral convergence modeling

11. Strategic Next Research Pathway

Next document in the SCF development chain:

SCF AEIC THERAPEUTIC STACK BLUEPRINT

This document converts the discovery map into:

final drug combinations
dosing architecture
pharmacokinetic modeling
IND-ready preclinical development plan

12. SCF Master Registry Index

SCF-AEIC-ADM-0001

SCF-AEIC-TPM-0001

SCF-AEIC-GL-0001

SCF-GCA-AEIC-0001

SCF-SEF-MD-0001

SCF-API-DP-0001

SCF-PP-UVT-0001

SCF-CRD-WORKFLOW-0001

SCF-VECTIS-409-PIPELINE-0001